---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-329570"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2026-08-03T12:03:40+00:00"
generated_at: "2026-08-03T12:05:04.666568+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics reports Q2 net loss of $20.2M; modifies RESTORE-FA trial, delays FECD data

## Summary
- Net loss of $20.2M for Q2 2026; cash and securities of $207.4M at quarter-end.
- RESTORE-FA trial modified: 12-week cohort at 1 mpk, primary endpoint endogenous FXN protein change; data expected Q1 2027.
- Phase 1 MAD trial of DT-818 in DM1 initiated; data expected in 2027.
- Phase 2 FECD trial of DT-168 delayed to 2027 due to supply issue with eye droppers.
- Registrational plan update expected Q4 2026.

## SEC filing metadata
- accession: 0001193125-26-329570
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2026-08-03T12:03:40+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000119312526329570/0001193125-26-329570-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000119312526329570/dsgn-20260803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-329570
- JSON: https://secwatch.observer/filing/0001193125-26-329570.json
- Plain text: https://secwatch.observer/filing/0001193125-26-329570.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.